NASDAQ: IRWD - Ironwood Pharmaceuticals, Inc.

Yield per half year: -29.38%
Sector: Healthcare

Download the report: word Word , pdf PDF

1. Summary

Advantages

  • Positive review The stock's return over the last year (-36.93%) is higher than the sector average (-50.75%).

Disadvantages

  • Negative review Price (6.78 $) is higher than fair price (6.06 $)
  • Negative review Dividends (0%) are below the sector average (1.871%).
  • Negative review Current debt level 151.88% has increased over 5 years from 124.6%.
  • Negative review The company's current efficiency (ROE=-654.88%) is lower than the sector average (ROE=11.82%)

2. Share price and performance

2.1. Share price

2.2. News

2.3. Market efficiency

Ironwood Pharmaceuticals, Inc. Healthcare Index
7 days 4.6% -100% -3.7%
90 days -55% -55.7% 2.8%
1 year -36.9% -50.7% 21.5%

Positive review IRWD vs Sector: Ironwood Pharmaceuticals, Inc. has outperformed the "Healthcare" sector by 13.81% over the past year.

Negative review IRWD vs Market: Ironwood Pharmaceuticals, Inc. has significantly underperformed the market by -58.38% over the past year.

Positive review Stable price: IRWD is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.

Long period: IRWD with weekly volatility of -0.7102% over the past year.

3. Summary of the report

3.1. General

P/E: 13.18
P/S: 3.96

3.2. Revenue

EPS -6.45
ROE -654.88%
ROA -127.54%
ROIC 66.79%
Ebitda margin 47.57%

4. Fundamental Analysis

4.1. Stock price and price forecast

The fair price is calculated taking into account the Central Bank refinancing rate and earnings per share (EPS)

Negative review Above fair price: The current price (6.78 $) is higher than the fair price (6.06 $).

Negative review Price is higher than fair: The current price (6.78 $) is 10.6% higher than the fair price.

4.2. P/E

Positive review P/E vs Sector: The company's P/E (13.18) is lower than that of the sector as a whole (89.01).

Positive review P/E vs Market: The company's P/E (13.18) is lower than that of the market as a whole (54.97).

4.2.1 P/E Similar companies

4.3. P/BV

Positive review P/BV vs Sector: The company's P/BV (-5.06) is lower than that of the sector as a whole (49.73).

Positive review P/BV vs Market: The company's P/BV (-5.06) is lower than that of the market as a whole (2.36).

4.4. P/S

Positive review P/S vs Sector: The company's P/S indicator (3.96) is lower than that of the sector as a whole (49.81).

Positive review P/S vs Market: The company's P/S indicator (3.96) is lower than that of the market as a whole (10).

4.4.1 P/S Similar companies

4.5. EV/Ebitda

Positive review EV/Ebitda vs Sector: The company's EV/Ebitda (11.28) is lower than that of the sector as a whole (61.32).

Positive review EV/Ebitda vs Market: The company's EV/Ebitda (11.28) is lower than that of the market as a whole (22.83).

5. Profitability

5.1. Profitability and revenue

5.2. Earnings per share - EPS

5.3. Past profitability Ebitda

Positive review Yield Trend: Rising and has grown by 6445.81% over the last 5 years.

Negative review Earnings Slowdown: The last year's return (0%) is below the 5-year average return (6445.81%).

Positive review Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-8.41%).

5.4. ROE

Negative review ROE vs Sector: The company's ROE (-654.88%) is lower than that of the sector as a whole (11.82%).

Negative review ROE vs Market: The company's ROE (-654.88%) is lower than that of the market as a whole (31.82%).

5.5. ROA

Negative review ROA vs Sector: The company's ROA (-127.54%) is lower than that of the sector as a whole (6.99%).

Negative review ROA vs Market: The company's ROA (-127.54%) is lower than that of the market as a whole (6.37%).

5.6. ROIC

Positive review ROIC vs Sector: The company's ROIC (66.79%) is higher than that of the sector as a whole (13.31%).

Positive review ROIC vs Market: The company's ROIC (66.79%) is higher than that of the market as a whole (10.68%).

6. Finance

6.1. Assets and debt

Negative review Debt Level: (151.88%) high relative to assets.

Negative review Increasing debt: over 5 years, the debt has increased from 124.6% to 151.88%.

Negative review Excess of debt: The debt is not covered by net income, percentage -71.39%.

6.2. Profit growth and share price

7. Dividends

7.1. Dividend yield vs Market

Negative review Low yield: The dividend yield of the company 0% is below the average for the sector '1.871%.

7.2. Stability and increase in payments

Negative review Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.

Negative review Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.

7.3. Payout percentage

Positive review Dividend Coverage: Current payments from income (63.5%) are at a comfortable level.

8. Insider trades

8.1. Insider trading

Positive review Insider Buying Exceeds insider sales by 100% over the last 3 months.

8.2. Latest transactions

No insider transactions have been recorded yet